Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.

Autor: Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola SA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Kudling T; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Jalkanen K; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Alanko T; Docrates Cancer Center, Helsinki, Finland., Monberg T; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Khammari A; Department of Dermatology, Nantes University, CHU Nantes, CIC1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France., Dreno B; Nantes University, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Block MS; Mayo Clinic Cancer Center, Minnesota, Rochester, USA., Adamo DA; Mayo Clinic Cancer Center, Minnesota, Rochester, USA., Mäenpää J; Docrates Cancer Center, Helsinki, Finland.; Faculty of Medicine and Medical Technology, and Cancer Center, Tampere University and University Hospital, Tampere, Finland., Kistler C; TILT Biotherapeutics Ltd, Helsinki, Finland., Sorsa S; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki O; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. akseli.hemminki@helsinki.fi.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Nov 06; Vol. 43 (1), pp. 297. Date of Electronic Publication: 2024 Nov 06.

Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.

Autor: Pakola SA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Peltola KJ; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Alanko T; Docrates Cancer Center, Helsinki, Finland., Korpisaari R; Docrates Cancer Center, Helsinki, Finland., Juteau S; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Jaakkola M; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Sormunen J; Docrates Cancer Center, Helsinki, Finland., Kemppainen J; Docrates Cancer Center, Helsinki, Finland., Hemmes A; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Pellinen T; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., van der Heijden M; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Kistler C; TILT Biotherapeutics Ltd., Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3715-3725.

Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.

Autor: Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Kerkelä E; Finnish Red Cross Blood Service, Helsinki, Finland., Pasanen A; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Anttila M; Pathology, Finnish Food Authority, Helsinki, Finland., Tapper J; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland., Kanerva A; Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. akseli.hemminki@helsinki.fi.

Publikováno v: Cancer gene therapy [Cancer Gene Ther] 2023 Dec; Vol. 30 (12), pp. 1679-1690. Date of Electronic Publication: 2023 Nov 10.

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.

Autor: Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Lähdeniemi IAK; Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLife, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Sutinen E; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland., Räsänen J; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Borenius K; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Mäyränpää MI; Pathology, University of Helsinki and Helsinki University Hospital (HUSLAB), Helsinki, Finland., Aaltonen E; Faculty of Medicine, Medicum, University of Helsinki, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki O; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Verschuren EW; Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLife, University of Helsinki, Helsinki, Finland.; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland., Ilonen I; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital (HUS), Helsinki, Finland.

Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Aug 02; Vol. 12 (1), pp. 2241710. Date of Electronic Publication: 2023 Aug 02 (Print Publication: 2023).

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.

Autor: Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Girych M; Department of Physics, University of Helsinki, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Pakola S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Hamdan F; Laboratory of ImmunoViroTherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Hemmes A; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland., Grönberg-Vähä-Koskela S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Basnet S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Heiniö C; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Kaptan S; Department of Physics, University of Helsinki, Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland., Erikat A; Department of Chemistry and the Randall Centre for Cell and Molecular Biophysics, King's College London, London, United Kingdom., Schwartz J; Chicago Department of Oral Medicine and Diagnostic Science, University of Illinois, Chicago, IL, United States., Anttila M; Pathology, Finnish Food Authority, Helsinki, Finland., Aro K; Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland.; Department of Otorhinolaryngology - Head and Neck Surgery, Helsinki Head and Neck Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Viitala T; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Vattulainen I; Department of Physics, University of Helsinki, Helsinki, Finland., Cerullo V; Laboratory of ImmunoViroTherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.; Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Kanerva A; Department of Gynecology and Obstetrics, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; R&D Department, TILT Biotherapeutics Ltd, Helsinki, Finland.; Research Program Unit (RPU), University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Feb 03; Vol. 14, pp. 1060540. Date of Electronic Publication: 2023 Feb 03 (Print Publication: 2023).